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An ACE inhibitor improves vascular outcomes in a PKD model
Surya M. Nauli
Department of Pharmacology, The University of Toledo, Toledo, Ohio
CARDIOVASCULAR COMPLICATIONS are the most common cause of
death in patients with polycystic kidney disease (PKD). Within
the context of clinical practice, two possible theories have been
reviewed that could help describe the pathogenesis of vascular
complications in PKD (7). Theory 1 points to inherent vascular
dysfunctions in solitary cilia as the primary cause of the
vascular complications. It has been shown that endothelial cells
lining the blood vessels possess primary cilia. In PKD, these
primary cilia fail to trigger a biochemical cascade in producing
vasodilator nitric oxide (NO) (4, 8), leading to abnormal
thickening of the blood vessels (3). Consistent with this view,
the plasma concentration of NO is reduced in PKD patients,
confirming an association between PKD and endothelial dys-
function (10, 11).
Theory 2 brings about the cystic kidney itself as the origin of
vascular complications. The enlarging renal cysts cause struc-
tural damage in the nephrons, which leads to distortion of the
renal architecture. This distortion compresses the renal vascu-
lature and attenuates the renal vessels, resulting in intrarenal
ischemia and activation of the renin-angiotensin-aldosterone
system (RAAS). Thus, as cysts enlarge, the RAAS is activated
(5), which is known to cause cardiovascular remodeling. Not
surprisingly, the angiotensin-converting enzyme inhibitor
(ACE-I) and/or the angiotensin receptor blocker (ARB) have
remained attractive clinical strategies in managing PKD pa-
tients (6).
The most recent work by Phillips et al. (9) in an issue of the
American Journal of Physiology-Renal Physiology showed
that the ACE-I perindopril was beneficial in maintaining proper
vascular structure and function in PKD rats. The structural and
functional indices of the blood vessels were assessed from the
measurements of blood pressure and arterial stiffness in vivo
followed by an analysis of calcification and structural integrity
of the blood vessels after the rats were euthanized. The authors
found that perindopril prevented an age-associated increase in
blood pressure. Furthermore, perindopril prevented an age-
related increase in arterial stiffness in PKD rats. When blood
vessels were isolated and examined more closely, calcium
deposits and arterial wall thickening were significantly atten-
uated with chronic perindopril treatment in PKD rats. Histo-
morphometric studies further indicated that the elastin-to-col-
lagen ratio within the blood vessels was significantly decreased
in PKD rats, but this declined ratio could be ameliorated with
chronic perindopril treatment.
Overall, the study suggests that perindopril can improve the
structural and functional indices of the vascular system in PKD
rats, demonstrating the clinical benefits of the ACE-I in slow-
ing down vascular remodeling in chronic kidney disease. All
parameters observed in these PKD rats, including increased
collagen, degeneration of elastin, increased wall thickness, and
decreased wall distensibility, are part of an arteriosclerotic
process and are commonly associated with vascular aging.
Consistent with this observation, we have shown that abnormal
vascular changes in PKD can be complicated by the aging
process (3).
Regardless of whether theory 1 on ciliopathy or theory 2 on
cystic expansion contributes to vascular complications in PKD,
Phillips and colleagues (9) provide an important step forward
in delineating vascular death in PKD. There is no doubt that
further biomedical research is urgently needed to understand
the complex cellular systems in the pathology of PKD. For
example, it has been recently shown that activation of ciliary
dopamine receptors can improve vascular function in PKD (1,
2). However, because our fundamental knowledge on cilia
function and cellular pathology of PKD is still very limited, it
remains unclear whether the same mechanism involving dopa-
mine receptors also works in cystic renal cells. Regrettably, we
currently have more questions than answers to offer.
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